NCT00397189View on ClinicalTrials.gov

Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

930

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

April 30, 2009

Conditions
Primary Insomnia
Interventions
DRUG

Circadin

Prolonged release melatonin 2 mg

DRUG

placebo circadin

placebo circadin tablets

Trial Locations (1)

G20 0XA

CPS Research, Glasgow

Sponsors
All Listed Sponsors
lead

Neurim Pharmaceuticals Ltd.

INDUSTRY

NCT00397189 - Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients | Biotech Hunter | Biotech Hunter